Histone Modifications as Biomarkers for Immunotherapy.
Explore this paper's citation graph
Summary
Promising advancements for using histone PTMs as immunotherapy responsiveness biomarkers in both cancer and immune cells are explored, and a methodological workflow for assaying histonePTMs in relevant samples is provided.
- Type
- review
- Published
- 2020-01-01
- Cited by
- 10
- References
- 92
- OpenAlex
- https://openalex.org/W2972829892
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:202412690
Keywords
Histone, Immunotherapy, Epigenetics, Computational biology, Cancer immunotherapy
References
- Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII
- High Expression of H3K27me3 in Human Hepatocellular Carcinomas Correlates Closely with Vascular Invasion and Predicts Worse Prognosis in Patients
- Histone modifications and cancer: biomarkers of prognosis?
- Epigenetics of human melanoma: promises and challenges.
- Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
- CD95(APO-1/Fas)-mediated apoptosis: live and let die.
- The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen.
- Big data in biomedicine
- A bivalent chromatin structure marks key developmental genes in embryonic stem cells.
- GLOBAL HISTONE MODIFICATIONS AS A PROGNOSTIC MARKER FOR BIOCHEMICAL RECURRENCE IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY
- The hallmarks of cancer
- The genomic landscape of histone modifications in human T cells
- Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition
- The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.
- Chemokines in Cancer
- Significance of Fas receptor protein expression in epithelial ovarian cancer.
- Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males
- Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.
- More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance
- High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma.
Cited by
- Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
- How to overcome the side effects of tumor immunotherapy.
- Beyond DNA-targeting in Cancer Chemotherapy. Emerging Frontiers- A Review.
- Assessment of alterations in histone modification function and guidance for death risk prediction in cervical cancer patients
- Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy.
- Histone modification‐linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter
- Integrated analysis of histone modification features in clear cell renal cancer for risk stratification and therapeutic prediction
- Advancing Epigenetic Combination Therapy in Oncology: Multifunctional Nano-Drug Delivery Systems for Synergistic Efficacy and Precision Modulation
- Epigenetics in disease prevention, cure, and treatment: Role of histone modifiers in immune modulation
Related papers
- Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
- B7-H3/CD276: An Emerging Cancer Immunotherapy
- pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
- New opportunities for nanoparticles in cancer immunotherapy
- Triggering Immune System With Nanomaterials for Cancer Immunotherapy
- The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications
- Nanotechnology in the arena of cancer immunotherapy
- Drug Delivery Strategies Based on Nanotechnology for Cancer Immunotherapy
- Nanotechnology Approaches to Improving Cancer Immunotherapy